Ovarian Stimulations

Four abstracts, including two oral and two poster presentations, highlight Ferring’s dedication and multi-focus approach to advancing fertility care PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals will present new data from four abstracts at the upcoming 2024 American Society for Reproductive Medicine (ASRM) Congress, being held October 19-23 in Denver, Colorado, and virtually. “We are pleased to share new data at this year’s ASRM Congress that provides healthcare professionals and fertility clinic staff with important research, findings and insights that they can apply in their clinical practice,” said Sasmira Lalwani, Senior Medical Director, Reproductive Medicine, Ferring Pharmaceuticals. “Our data presentations underscore our goal of advancing the science, supporting diverse family-building needs and providing educational resources for healthcare professionals because we understand there’s not a ‘one-size-fits-all’ approach to fertility care.” The four abstracts being presented by Ferring cover a wide range of timely and critical topics in reproductive medicine. Abstract Title Presentation Details - All times MDT Advancing Fertility Equity: Uplifting Black Women’s Voices to Design Culturally Responsive Support Solutions Poster #24 EMBARGOED UNTIL: October 21 10:45 – 11:00 a.m. Patterns of Utilization of Advanced Practice Providers in Reproductive Endocrinology: A 2023 National Survey Oral Presentation #184 EMBARGOED UNTIL: October 22 11:45 – 11:56 a.m. Impact of Gonadotropin Selection on Risk of Ovarian Hyperstimulation Syndrome (OHSS) in Predicted High Responders Undergoing Ovarian Stimulation: A Megaset-HR Trial Analysis Oral Presentation #154 EMBARGOED UNTIL: October 22 10:56 – 11:07 a.m. Assessing the Impact of an eLearning Platform for Educating Fertility Professionals Poster #652 EMBARGOED UNTIL: October 23 11:30 – 11:45 a.m. “For more than 50 years, Ferring has been relentless in our pursuit to help more people become parents by working to address the evolving needs within reproductive medicine,” said David Powley, Vice President, Reproductive Medicine and Operations, Ferring Pharmaceuticals. “ASRM is an important opportunity to share more about our contributions and long-standing investment in areas such as our product portfolio and pipeline, focus on expanding access to in vitro fertilization and work with healthcare professionals to help improve the patient experience and outcomes.” Along with the four data presentations, Ferring will also host an informative discussion entitled “Addressing Gaps and Reaching More Patients: Impacting Family Building Through Advocacy and Legislation” (October 21st at 10:05 a.m. MDT). The moderated panel discussion highlights the state and federal legislative, policy and health equity advances to expand access to family building care and infertility treatment. Moderator : Tim Clark, Director of Government Affairs, Ferring Panelists : Serena H. Chen, MD, Reproductive Endocrinologist, Division Director Emeritus & Director of Advocacy, CCRM NJ - IRMS Reproductive Medicine Michael A. Thomas, MD, Professor and Chair, Department of Obstetrics and Gynecology, University of Cincinnati College of Medicine and Immediate Past President, American Society for Reproductive Medicine Sean B. Tipton, MA, Chief Advocacy & Policy Officer, American Society for Reproductive Medicine About Ferring Pharmaceuticals Ferring Pharmaceuticals is a privately-owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. In the United States, Ferring is a leader in reproductive medicine, and in areas of gastroenterology and orthopaedics. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Our company was founded in 1950 and is headquartered in Saint-Prex, Switzerland. Ferring employs more than 7,000 people worldwide and markets its medicines in over 100 countries. Ferring USA is based in Parsippany, New Jersey, and employs more than 900 employees. For more information, please visit , call 1-888-FERRING (1-888-337-7464), or connect with us on LinkedIn , and X (Twitter) . Contacts For more information, please contact: Lisa Perdomo Director, Brand Communications Ferring Pharmaceuticals +1-862-341-9820 lisa.perdomo@ferring.com

NEW YORK, April 2, 2024 /PRNewswire/ -- Gameto, a female-led biotechnology company with a mission to redefine women's healthcare, today announced encouraging new findings from a study evaluating how minimal controlled ovarian stimulation (COS) in combination with Fertilo, their novel investigational in vitro maturation (IVM) solution containing engineered ovarian support cells (OSC-IVM) to mature eggs outside of the body, affected patients' egg retrieval experiences when compared to conventional stimulation. The data analysis found that women undergoing minimal hormonal stimulation for OSC-IVM reported experiencing few side effects, lower levels of pain after retrieval, and higher satisfaction levels with the shortened stimulation procedure, compared to conventional stimulation for in vitro fertilization (IVF). "This study is significant because female patients' pain, morbidity, and inconvenience are frequently minimized and neglected in the healthcare setting, and often more so for women pursuing fertility treatments and egg or embryo freezing," said Dr. Dina Radenkovic, Chief Executive Officer and co-founder of Gameto. "We are encouraged by these and previously published efficacy data which demonstrate that combining minimal hormonal stimulation with our investigational in vitro maturation solution may help women navigating fertility treatments avoid many of the common side effects associated with the conventional IVF hormone protocol. We care about the efficacy but also about the experience." Fertilo, Gameto's lead investigational program, is a solution derived from induced pluripotent stem cells (iPSC) and designed to mature eggs outside of the body as part of minimal hormonal stimulation cycles for in vitro fertilization and egg freezing. Fertilo is cleared for commercialization in Australia and in large markets in Latin America. Gameto's goal in developing Fertilo is to make fertility treatments more convenient, safer, and accessible for a wider patient population. In the retrospective survey study, the minimal stimulation OSC-IVM cycles were associated with significant reductions in reported side effects and levels of pain. The data analysis found that severe pain was reported by 38.46% of patients undergoing conventional COS compared to only 7.69% of participants in the minimal stimulation OSC-IVM cohort. The majority of women in the minimal stimulation OSC-IVM cohort did not experience common IVF side effects: 86% reported no breast swelling, 76% reported having no pelvic or abdominal pain, 96% reported having no nausea or vomiting, and 96% reported having no bleeding. Approximately one-third of patients undergoing conventional COS experience ovarian hyperstimulation syndrome (OHSS), a painful and potentially dangerous response to the conventional stimulation protocol, with one to five percent of cases requiring hospitalization.[1],[2] In contrast, the participants in this analysis who underwent minimal ovarian stimulation cycles followed by OSC-IVM yielded no incidence of OHSS. Furthermore, in patients who went through both cycles, 92% of patients expressed they would repeat the minimal stimulation followed by OSC-IVM cycle, relative to 77% in conventional stimulation with IVF. The retrospective survey analysis included a comparison between 110 patients who underwent minimal stimulation cycles followed by OSC-IVM, versus 48 patients who underwent conventional stimulation cycles, and a pairwise comparison with data from 13 patients who themselves underwent both cycles. The manuscript describing these data is available on a preprint server at https://www.medrxiv.org/content/10.1101/2024.03.28.24304995v1 and is concurrently undergoing scientific peer-review for potential publication. Gameto is currently engaged in rigorous preparations to meet the FDA's conditions for Phase 3 trial initiation. For more information about Gameto and how the company is redefining women's healthcare, visit gametogen.com. About Gameto Gameto is a biotechnology company developing novel treatment solutions for women's health, starting with infertility. Gameto brings together an experienced scientific management team with the vision and passion to develop a product suite to support women throughout their reproductive journeys. Gameto's lead program, Fertilo, aims to make IVF and egg freezing shorter, safer, and more accessible through reduced hormonal injections by maturing eggs outside of the body. Gameto is led by physician-turned-entrepreneur Dina Radenkovic as CEO and serial entrepreneur and founder of North America's largest fertility network Prelude Fertility, Martin Varsavsky, as Chairman. For more information, go to gametogen.com or follow us on Twitter and Instagram @gametogen and on LinkedIn.

Qualified study participants will receive free in vitro maturation treatment at CCRM Fertility DENVER, April 4, 2023 /PRNewswire/ -- CCRM Fertility, a global pioneer in fertility treatment, research and science, is seeking participants for a new study on in vitro maturation (IVM). IVM requires less hormones to stimulate the ovaries than IVF, making it more affordable than IVF with fewer side effects. Participants that qualify for the study will receive a free cycle of IVM treatment at CCRM Fertility including a new patient consultation, fertility testing, preimplantation genetic testing for aneuploidies (PGT-A), anesthesia and some medication. "IVM works by minimal stimulation of the ovaries with injectable hormones and after a few days, the immature eggs are retrieved from the patient, and are then matured in our state-of-the-art IVF lab," said CCRM Fertility Research Director Ye Yuan, Ph.D. "Based on our published research, CCRM Fertility has developed a new maturation system that helps these eggs mature successfully. Once mature, the process is identical to a typical IVF cycle." No longer considered experimental by the American Society of Reproductive Medicine (ASRM), IVM requires significantly less hormonal stimulation than IVF, which dramatically reduces the number of injections patients must receive. It also reduces the side effects often present with hormone treatment, and virtually eliminates the risk of ovarian hyperstimulation syndrome (OHSS), which causes the ovaries to swell and can cause severe pain. IVM could be especially beneficial to individuals who are at greater risk of OHSS, such as those with polycystic ovary syndrome (PCOS). "While IVM is offered in other countries internationally, CCRM Fertility is paving the way to bring this treatment to the U.S., allowing alternative and less invasive options for individuals, particularly those with PCOS, looking to start, grow or complete their families," said Dr. Yuan. In two previous IVM studies conducted by CCRM Fertility, initial results found that 41% of PCOS patients who had received IVM treatment have had live births or an ongoing pregnancy. The patients in these studies had poorer prognosis (due to age and other complications) than CCRM Fertility's targeted patients for its upcoming clinical trial. CCRM Fertility expects at least comparable or even better outcomes for its current study. For inclusion in the IVM study, all of the following criteria must be fulfilled: Ages 18 – 38 years old Infertile women diagnosed with PCOS or polycystic ovaries, or infertile women with good ovarian reserve Antral follicle count (AFC) greater than 24 AMH greater than 3.5 ng/ml Body Mass Index less than 35 Accept to have embryos biopsied for PGT Intend to perform embryo transfer within 4 months after completing the IVM cycle Paternal (or donor) age <45, ejaculated sperm collection only (partner frozen and donor sperm acceptable), sperm morphology (strict criteria) >1%, motility > 20% and sperm count > 10 million per ml (so samples can be prepared through standard procedure) Patients may not have had more than two failed IVF cycles in the past. To learn more, please reach out to Rachel Makloski at [email protected]. To be considered for the IVM study, please fill out the following form. About CCRM Fertility CCRM Fertility is a global pioneer in fertility treatment, research and science. Founded by Dr. William Schoolcraft over 35 years ago, CCRM Fertility specializes in the most advanced fertility treatments, with deep expertise in IVF, fertility testing, egg freezing, preimplantation genetic testing, third party reproduction and egg donation. CCRM Fertility leverages its own data and a dedicated team of in-house reproductive endocrinologists, embryologists and geneticists to deliver industry-leading outcomes. CCRM serves 13 major metropolitan areas with 36 locations across North American, including Atlanta, Boston, Dallas-Fort Worth, Delaware, Denver, Houston, New Jersey, New York, Northern Virginia/D.C., Minneapolis, Orange County, San Francisco Bay Area, and Toronto. CCRM Fertility is a proud strategic partner of Unified Women's Healthcare, the leading platform for women's health services. Together with our affiliated providers and businesses, we anticipate the greatest opportunities to impact every woman's health at every stage of her journey and are unparalleled in our scale and ability to adapt to address unmet and underserved needs. For more information, visit . SOURCE CCRM